Provention Bio Inc

NASDAQ:PRVB  
4.08
+0.18 (+4.62%)
Earnings Announcements

Provention Bio Announces Positive Final Results From First-In-Human Study Of Coxsackievirus B Vaccine Candidate Prv-101

Published: 03/28/2022 11:52 GMT
Provention Bio Inc (PRVB) - Provention Bio Announces Positive Final Results From First-in-human Study of Coxsackievirus B Vaccine Candidate Prv-101.
Provention Bio Inc - Prv-101 Continued to Be Well Tolerated.
Provention Bio Inc - Prv-101 Met Primary Endpoint Confirming Tolerability Observed in Previously Reported Interim Analysis.
Provention Bio Inc - Results Also Showed Durability of Viral Neutralizing Antibody (vnt) Responses.
Revenue is expected to be $0.73 Million
Adjusted EPS is expected to be -$0.50

Next Quarter Revenue Guidance is expected to be $0.83 Million
Next Quarter EPS Guidance is expected to be -$0.72

More details on our Analysts Page.